Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cariprazine
- Development stage
- Approved
- Lead developer
- Gedeon Richter
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Cariprazine is an atypical antipsychotic and a piperazine derivative used primarily for the treatment of schizophrenia and bipolar I disorder, including manic, mixed, and depressive episodes. It is also approved as adjunctive therapy for major depressive disorder (MDD) in adults. Cariprazine acts mainly as a partial agonist at central dopamine D2 and D3 receptors (with higher affinity for D3), as well as serotonin 5-HT1A receptors, and functions as an antagonist at serotonin 5-HT2A receptors. The drug was first developed in Hungary by Gedeon Richter[1][5]. Its mechanism of action involves modulating neurotransmitter activity in the brain to reduce psychosis, mania, depression, and related symptoms[1][3][4].
- Brand names
- Vraylar
- Other names
- cariprazine hydrochloride
02
Targets
DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)HRH1 (Histamine H1 Receptor)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)HTR2B (5-Hydroxytryptamine Receptor 2B)HTR2C (5-hydroxytryptamine 2C receptor)
Beyond the preview
Go deeper on cariprazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cariprazine.